Saperstein_2004_Semin.Neurol_24_41

Although once a severe and often fatal illness, myasthenia gravis can now be well managed with several relatively safe and effective therapies. Management involves a graded approach, beginning with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. There are several immunomodulating agents from which to choose; selection is based largely on time to clinical effect and adverse effects. This review will discuss the selection and use of therapies for patients with myasthenia gravis.